Martin Shkreli raised the price of Daraprim from $13.50 to $750 overnight, highlighting issues in the US pharmaceutical industry where drug companies prioritize profits over patients. While drug companies claim high prices are needed to fund research, they actually spend more on marketing than R&D. Additionally, drug prices rise beyond inflation rates each year even as demand decreases. The US spends 40% more on pharmaceuticals than other countries due to a lack of regulation and bargaining power over drug prices, resulting in many Americans being unable to afford necessary medications.